Jonathan Sagum, MD
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1629236658
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,848 and has fallen 94.5% since, to $157 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KY, where the typical reported total is $3,450.
Across 257 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$547
- Lilly USA, LLC$419
- Sanofi-aventis U.S. LLC$344
- Amgen$308
- Johnson & Johnson$258
- Medtronic$257
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,69797%
- Education$1053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $547 |
| Lilly USA, LLC | 32 | $419 |
| Sanofi-aventis U.S. LLC | 21 | $344 |
| Amgen | 24 | $308 |
| Johnson & Johnson | 24 | $258 |
| Medtronic(2 entities) | 6 | $257 |
| Abbott | 7 | $234 |
| Insulet Corporation | 16 | $209 |
| Boehringer Ingelheim | 18 | $205 |
| Radius Health, Inc. | 8 | $191 |
| AstraZeneca | 11 | $183 |
| Dexcom, Inc. | 10 | $137 |
| Amarin Pharma, Inc. | 8 | $109 |
| Tandem Diabetes Care, Inc. | 4 | $88 |
| AbbVie | 6 | $83 |
| Shire North American Group Inc | 4 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Merck | 2 | $23 |
| Antares Pharma, Inc. | 1 | $21 |
| Senseonics, Incorporated | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Pfizer | 1 | $13 |
| Companion Medical, Inc. | 1 | $12 |
| IBSA Pharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$157
- FREESTYLE LIBRE 3$102
How this compares
$3,802 in reported general payments places this provider in the 50th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 183 | $350,790 |
| TrulicityDulaglutide | 186 | $334,901 |
| JardianceEmpagliflozin | 119 | $171,891 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $92,928 |
| FarxigaDapagliflozin Propanediol | 61 | $82,863 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $82,820 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $65,209 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $64,067 |
| MounjaroTirzepatide | 41 | $63,594 |
| TymlosAbaloparatide | 23 | $56,920 |
| JanuviaSitagliptin Phosphate | 41 | $55,185 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $48,302 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $21,611 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $20,422 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $19,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $419 | $407,862244 claims |
| Novo NordiskOzempic | $547 | $350,790183 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $205 | $210,372154 claims |
| AstraZenecaFarxiga | $183 | $82,86361 claims |
| Radius Health, Inc.Tymlos | $191 | $56,92023 claims |
| MerckJanuvia | $23 | $55,18541 claims |
| PfizerGenotropin | $13 | $16,74311 claims |
| AbbVieSynthroid | $83 | $16,229161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Mehdi PoorkayLouisville$81K
- Angelino YsonLouisville$15K
- Mary SelfLouisville$14K
- Omolara FakunleLouisville$13K
- Kaitlyn TuckerLouisville$9K
- Manikya KuritiLouisville$7K
- Carol ToumaLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.